China play and research into cancer. Aida Pharmaceuticals (“Aida”) is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sale and marketing of advanced pharmaceutical products in mainland China. Aida’s mission is to discover, develop and market meaningful new therapies that improve human health. The Company created, tested, marketed and distributed the first antibiotic developed in China. Aida, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP and ISO9002 certified for global quality assurance and ISO14000 certified for ecologically-friendly practices. Growth Potential Overall sales for Aida Pharmaceuticals are expected to increase at a rate of 35% per year over the next five years. Aidal Pharmaceuticals believes that the continued double-digit growth in the company’s sales and profits are attributable to the product innovation, efficient operational infrastructure and value-added services that Aida delivers on a daily basis.

Green energy in the South American market. Has been the victim of "pump and dump" but this did not put us off. PURE Biofuels is committed to being a leader in Latin America's rapidly emerging biofuels industry. PURE Biofuels' flagship project, the Callao Port biodiesel refinery near Lima, Peru, is scheduled to commence production in the fist half of 2008. The Callao Port refinery will process biodiesel from crude palm oil feedstock. PURE Biofuels has secured memorandums of understandings with local fuel distributors for all of Callao Port's annual biodiesel production. From the company:- As a company, we are responsible to our shareholders. We are in business to make a profit. It is our shareholders' vision of a profitable and ethical company that enables us to grow as we continue to develop new operations and new markets for our biodiesel.

Consolidation in the Medical Equipment market. Andover Medical, Inc. (AMI) has recently stated that they anticipate that their revenue will double in 2008. Andover Medical, is seeking to take advantage of projected growth and evolving economies of scale arising from consolidation in the procedure specific durable medical equipment (DME) and services segments of the orthopedic, podiatric, and urological physician care markets in the United States. By establishing a nationwide subsidiary network, AMI plans to offer physicians the largest selection of competitively priced brand-name DME, and urodynamic diagnostic and treatment products. Orthopedics, urology and podiatry are among the fastest growing segments in healthcare products and services. The baby-boomer and the graying of the population with the increase in the active physical lifestyle of seniors, among other factors, play key roles in this growth. Market Highlights: The U.S. DME orthopedic product market is estimated to be a $1.02 billion dollar industry. It is probable that 10 percent of all patients seen by the 2,700 orthopedic clinics require a prescription of DME products. The $16 billion podiatry industry is served by 14,000 podiatrists. The DME incontinence product market now exceeds $2 billion and is expected to grow rapidly based both on the size of the senior population and its desire for a better quality of life. This company was also of victim of "pump and dump"

Growth Company and was recently given a buy rating Ciena specializes in helping their customers transition their networks for maximum value using innovative technology and market-driven solutions that address end-user demand. With expertise in optical, access and data networking, Ciena enables their customers to deliver more services faster, lower the network cost base, and improve the end-user experience. Their website load really fast compared with others

Takeover play

Technology in hotels, universities and hospital - a growing market and have expanded into the Far East hotel market this year Superclick has deployed and installed its SIMS™ products, as well as provisioning of customer support through its in-house call center located in Montreal, Canada, to customers throughout North and South America, Caribbean, Europe and the Middle East. The Company’s call center support is multi-lingual, with representatives serving English, French, Spanish, Italian, Greek, Arabic and Hebrew speaking customers. Their automated Interactive Voice Response service can also serve customers in English, French and Spanish. All support calls, originating from installations outside of North America are supported by Voice over Internet Protocol ("VoIP") into their Network Operating Center ("NOC"). This eliminates the expense of long distance fees for customer properties.

Fuel Cells. The company´s share price has fallen quite sharply since a report from Beacon Equity giving it a "speculative buy" rating and could now be the time to add to a long term portfolio VIASPACE is dedicated to commercializing proven space and defense technologies from NASA and the Department of Defense into hardware and software products. VIASPACE is developing these technologies into hardware and software products that we believe have the potential to fulfill high-growth market needs and solve today’s complex problems. The Company has expertise in energy/fuel cells, microelectronics, sensors and software for defense, homeland security and public safety, information and computational technology. VIASPACE has licensed patents, trade secrets, and software technology from California Institute of Technology (“Caltech”), which manages the Jet Propulsion Laboratory (“JPL”) for NASA. This technology was developed by scientists and engineers at JPL over the last decade and was funded by NASA and the Department of Defense. VIASPACE is working to leverage this large government research and development investment – made originally for space and defense applications – into commercial products.

A laggard! before the reverse split of 1 for 10 in about 2000 the shares hit $100 + when they owned Altvisa. Shouldn´t @Ventures add some spice to the share price? CMGI, Inc. (Nasdaq: CMGI), through its subsidiary ModusLink, provides industry-leading global supply chain management services and solutions that help businesses market, sell and distribute their products around the world. In addition, CMGI's venture capital business, @Ventures, invests in a variety of technology ventures. @Ventures, CMGI's venture capital business, invests in early-stage and mid-stage technology companies. Formed in 1995, @Ventures has funded more than 75 Internet, software, IT and clean energy companies. The primary focus of @Ventures’ fifth fund, formed in 2004, is on investments in clean energy technologies, including alternative energy, energy efficiency, and water purification and management.